SB 657510
SIGMA/S7326 - ≥98% (HPLC)
Synonym: 2-
CAS Number: 474960-44-6
Empirical Formula (Hill Notation): C19H22BrClN2O5S
Molecular Weight: 505.81
Linear Formula: C19H22BrClN2O5S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C19H22BrClN2O5S/c1-23- |
| InChI key | KQCZCINJGIRLCD-CYBMUJFWSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | COc1cc(Br)c(cc1OC)S(=O)(= |
| solubility | DMSO: ≥30 mg/mL |
| storage temp. | room temp |
| Application: | SB 657510 may be used to study the urotensin II receptor-mediated signaling. |
| Biochem/physiol Actions: | SB 657510 is a potent and selective urotensin-II (UT) receptor antagonist. |
| Biochem/physiol Actions: | SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.1 |
| Biochem/physiol Actions: | SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease states, including heart failure, atherosclerosis, hypertension. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P261 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |


